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Biomedical science and technology are developing at a more rapid pace than ever. Investments in health research and development (R&D) have never been 
higher—global spending on health research increased from 
US$30 billion in 1990 to US$105.9 billion in 2001. But despite 
advances in technology and unparalleled research spending, 
the medical needs of many of the world’s population go 
unmet. For example, only 1% of new drugs approved between 
1975 and 1999 were speciﬁ cally developed for tropical 
diseases and tuberculosis—diseases that account for over 10% 
of the global disease burden (Figure 1) [1].
In recent years, some important steps have been taken to 
improve access to existing treatments in the developing world 
by increasing generic competition. Yet there continues to be a 
tension between promoting access to lifesaving medicines as a 
human right and maintaining a global trade regime that seeks 
to ﬁ nance health R&D by allowing monopolies to charge high 
prices [2]. 
There is a growing demand from many quarters for a new 
international policy framework [3]. A new international treaty 
on essential health R&D could provide a binding framework 
to redirect today’s knowledge and scientiﬁ c expertise to 
priority health needs. The treaty could help to cement new 
political commitments and coordinate complementary 
partnerships aimed at generating and rewarding health 
innovation as a global public good.
The Patent System: An Unhealthy Motive 
for Medical Innovation?
Until recently, providing patent protection for 
pharmaceuticals was a choice made by individual 
governments according to their level of industrial 
development. Today, pharmaceutical patents are globalized 
through the World Trade Organization’s Agreement on 
Trade-Related Aspects of Intellectual Property Rights (TRIPS 
Agreement) [4], and then further reinforced through 
bilateral and regional arrangements (the so-called TRIPS-Plus 
agreements [5]). But the patent system stimulates innovation 
only where industry sees the opportunity for increasing sales 
and market share; much of the resulting “innovation” is in 
fact imitation, producing “me-too” drugs that offer little, if 
anything, in the way of therapeutic beneﬁ t over existing drugs 
(Box 1). 
The poorest are hardest hit. While R&D of new therapies 
against tropical diseases has ground to a standstill, 14 million 
people die from infectious diseases each year, predominantly 
in developing countries [1]. Most of the world’s 40 million 
people with HIV/AIDS, including 2.2 million children under 
15, live in the developing world (www.unaids.org). The poor 
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Figure 1. Clinical Offi cer Preparing Sodium Stibogluconate Solution 
Injection for a Patient with Visceral Leishmaniasis
Sodium stibogluconate solution is administered by intramuscular 
injection for 30 days. The injection is painful and can cause toxic 
reactions. Developed in 1934, resistance of up to 65% has been 
documented in India. Around 50,000 people die from visceral 
leishmaniasis each year. New, effective drugs and diagnostics are 
urgently needed.
(Photograph: Copyright Espen Rasmussen/MSF, Somalia, 2004)
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also dominate non-communicable disease tables, accounting 
for 59% of the 56.5 million annual global deaths [6]. 
The patent system is also promoting new inequalities in 
high-income countries. Americans now spend a staggering 
$200 billion a year on prescription drugs. This ﬁ gure is 
growing at a rate of about 12% per year [7]. The average 
price of the ﬁ fty drugs most used by senior citizens in America 
was nearly $1,500 for a year’s supply in 2002. Prescription 
drugs have become inaccessible even to many people in the 
rich world.
Patents, with their focus on maximizing proﬁ ts, have at 
least three negative consequences. First, it has been argued 
that the patent system causes substantial welfare losses 
because consumers who would buy the product if it were 
priced at somewhere nearer production cost do not buy it 
at the monopoly price [8]. Second, the system encourages 
counterfeiting—counterfeit drugs may represent up to 10% 
of the global market for pharmaceuticals [9]. Third, patented 
drugs are promoted through excessive marketing—on 
average, twice as much is spent on marketing a drug as on 
its R&D [10]. Across industries, it is becoming increasingly 
apparent that the patent system isn’t working well [11], 
leading some in industry to express public concern that the 
blockbuster business model is “irreparably broken” [12]. A 
new approach is needed, for all our sakes.
Prescriptions for an Innovative Approach: A New 
Treaty for Essential Health R&D
The only major international policy instrument that exists 
today to stimulate and ﬁ nance health R&D is the TRIPS 
Agreement [4]. The TRIPS Agreement provides 20 years 
of patent protection on pharmaceuticals in the hope of 
stimulating the development of new medicines. Beyond 
that, governments try to stimulate R&D in neglected areas 
by providing industry with incentives such as tax breaks and 
patent extensions. However, the effectiveness of these policies 
is hardly known. 
In 2001, the Doha Declaration on TRIPS and Public 
Health afﬁ rmed the sovereign right of WTO members 
to take measures to protect public health by overcoming 
patents whenever needed [4]. The last few years have seen 
increased attention to the fact that patents keep drug costs 
high and limit access to medicines. However, there has been 
no movement in international policy to address the crisis in 
pharmaceutical innovation. 
Health R&D must be treated as an international problem 
that requires an international solution. It should be treated 
like other strategic sectors, as happens today for defense and 
space discovery—sectors that both beneﬁ t from very strong 
government support for innovation. When global public 
goods do correspond to national needs, governments should 
step in to mobilize and enforce the collective action required. 
For example, global cooperation in the sharing of infectious 
disease monitoring from 1890 onwards set a valuable 
precedent [13]. 
The recent epidemic of severe acute respiratory 
syndrome—SARS—clearly shows that biomedical knowledge 
and the pharmaceutical sciences can be mobilized to 
achieve rapid advances relevant to social needs if sufﬁ cient 
resources and political will can be mustered. The SARS virus 
was completely sequenced in just six days, and a diagnostic 
test was developed in only three months. The public-sector 
funded, collaborative “public-goods model” used for the 
Human Genome Project shows that public collaborative 
research can be more efﬁ cient than the closed, monopolistic, 
private sector approach.
An international treaty (Box 2) would promote a health-
needs-driven approach to drug discovery. The elaboration 
of such a treaty would have to meet the two crucial 
requirements for an effective system of funding innovation in 
pharmaceuticals. First, the reward for innovation should be 
proportional to the social (that is, therapeutic) value. Second, 
prices should be near average production cost. 
The idea is to shift the discourse from trade to health. 
The treaty—focussed directly on R&D rather than patent 
rights or drug prices—would address the global management 
of publicly funded health R&D. Priorities for R&D would 
Box 1. How Innovative Is the Profi t Motive?
• A study published in the Lancet in 2002 showed that 68% of all 
new chemical entities marketed worldwide in the last 25 years 
were me-too products, representing little or no therapeutic gain 
[1].
• According to the United Nations Development Programme, 
less than 5% of drugs introduced by the top 25 pharmaceutical 
companies in the US represented true therapeutic advances; of 
these, 70% were developed with government involvement ([20], 
p. 69). 
• Studies of drug development over the last decade in the US [21] 
and the last two decades in France [23] show that around two-
thirds of medicines are me-too products. 
• 92% of medicines approved in 2002 by the US Federal Drug 
Administration were me-too drugs [23].
February 2005  |  Volume 2  |  Issue 2  |  e14
DOI: 10.1371/journal.pmed.0020014.g002
Figure 2. Detection of African Sleeping Sickness by Lumbar Puncture
Lumbar puncture in patients with African sleeping sickness can 
be a painful and potentially dangerous maneuver that is the only 
way to determine if the disease has progressed to the second 
stage. New diagnostic tools are urgently needed, as are new 
treatments; current medicines are old, toxic, difﬁ cult to use, and 
their production is not guaranteed. Around 60,000 people die 
from Aﬁ can sleeping sickness every year.
(Photograph: copyright Serge Sibert/MSF, Uganda, 1998.)
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be deﬁ ned through public-sector leadership and based on 
public health needs. R&D opportunities would be aimed 
at new lead compounds, new types of health tools (Figure 
2) and new treatment approaches. As the only legally 
mandated international government agency responsible for 
global health, the World Health Organization should work 
toward establishing this essential R&D agenda. Individual 
states would need to periodically evaluate targets for priority 
research and make adequate recommendations toward needs-
driven R&D. 
How Will the Treaty Work?
One of the main objectives of the treaty would be to 
encourage the broad dissemination of information and 
knowledge-sharing, and to support diversity, competition, 
and collaboration among researchers from developed and 
developing countries. 
There are already precedents for the free, public sharing 
of innovations with the aim of developing new drugs. The 
Tropical Diseases Initiative (www.tropicaldisease.org), for 
example, is a new, Internet-based, community-wide effort to 
develop new drugs for tropical diseases [14]. The BioBricks 
project (http:⁄⁄parts.mit.edu/) at the Massachusetts Institute 
of Technology is exploring standardized tools and processes 
for DNA work, largely by computer. The Bios Initiative 
(Biological Innovation for Open Society), launched by the 
Australian non-proﬁ t organization Cambia (the Center 
for the Application of Molecular Biology to International 
Agriculture; www.cambia.org), is an effort to develop new 
innovation systems for market failures and for neglected 
priorities [15]. 
Among other incentives, technology exchange frameworks 
could include licensing agreements with developing 
countries, or afﬁ rmative commitments of research funds for 
collaborative projects with these countries. Such collaboration 
is currently being implemented in Europe, for example, 
through the European and Developing Countries Clinical 
Trial Partnership (www.edctp.org) [16]. The partnership is a 
new funding body established to fund research in developing 
countries, particularly in Africa, which contributes to the 
development of affordable prophylactics and drugs for HIV/
AIDS, tuberculosis, and malaria. The treaty on health R&D 
should also promote partnerships between countries in the 
developing world and encourage the creation of regional 
technology networks in developing countries.
Much of today’s drug development know-how exists 
within the private sector. Further work is needed to deﬁ ne 
obligations and incentives in the treaty that maximize 
industry contributions to publicly funded R&D by providing 
in-kind contributions in areas where industry has the skills 
that public groups need. The treaty should also provide an 
expanded use of government rights against patent abuse on 
drugs developed with public support. This would include 
the right of a government to intervene if an invention is not 
made available to the public on reasonable terms, such as is 
included in the march-in rights clause of the United States’s 
1980 Bayh-Dole Act (which enabled public universities to 
license inventions for commercial development [17]).
Making the Treaty Happen
There are a number of obvious difﬁ culties in moving the 
treaty forward, and these should not be underestimated. 
A delicate issue is the treaty’s relation with other binding 
agreements, particularly the TRIPS Agreement. Governments 
that join the treaty should be granted patent exceptions and 
should not be accused of “free-riding,” since they would be 
contributing to R&D through a different juridical avenue. 
Substantial government resources would need to be 
mobilized to ﬁ nance the highest priority medical research. 
All governments should participate according to their means. 
Countries already contribute signiﬁ cantly to global R&D 
through the purchase of costly patented drugs. Among other 
measures, not-for-proﬁ t initiatives working to develop new 
drugs, vaccines, and diagnostic tools for neglected diseases 
should be funded at levels that enable them to reach their 
objectives. Recent examples clearly show that when political 
will is mobilized, resources are rapidly made available to 
generate R&D in a particular area. In 2001, the anthrax scare 
in the US led to increases in biodefense research spending at 
the US National Institutes of Health from US$53 million in 
2001 to US$1.6 billion in 2004.
A treaty on health R&D is certainly a feasible proposal—the 
successful adoption of a treaty on plant genetic resources 
shows that it can be done. After seven years of negotiations, 
the Food and Agriculture Organization of the United Nations 
adopted the International Treaty on Plant Genetic Resources 
for Food and Agriculture in November 2001 [18]. This legally 
binding treaty covers all plant genetic resources relevant for 
food and agriculture. Through the treaty, countries agree to 
establish an efﬁ cient, effective, and transparent multilateral 
system to facilitate access to plant genetic resources for 
food and agriculture, and to share the beneﬁ ts in a fair and 
equitable way. While there has been a growing consensus in 
development circles that more international public goods 
need to be supplied as part of the development strategy, 
increasing their provision will be inﬂ uenced by the extent 
to which inspirational groups of individuals step in to play a 
leadership role to meet the collective need. 
Box 2. Key Concepts of an R&D Treaty
A global, needs-driven R&D agenda: allowing policy makers, 
funding agencies, and the research community to set priorities 
for developing safe, effective, and affordable medicines 
according to health needs. 
Prioritization for neglected diseases: to ensure that immediate 
efforts are made toward fi nding new tools for lethal diseases that 
are currently diffi cult or impossible to diagnose and treat.
Adequate international fi nancing of health R&D: a new 
funding mechanism is urgently needed to support R&D on 
an ongoing basis, particularly for neglected diseases. All 
governments will need to participate according to their means. 
Equitable pricing: governments should ensure that the poor 
also have access to innovations resulting from government-
funded or university research. 
Open access: governments should require access to the 
compounds and tools that result from public research in order to 
stimulate follow-on innovation elsewhere.
International exchange: strengthening openness and transfer 
of technologies on a global basis will greatly help developing 
countries by improving access to information and ideas and 
accelerating the development of science and technology. 
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The Ottawa Convention to Ban Anti-Personnel Landmines 
and the 2003 Framework Convention on Tobacco Control 
show that international frameworks are essential to the 
regulation of the private sector for the good of global health. 
The World Health Organization, together with other relevant 
United Nations agencies, has full legitimacy to work with 
member states toward crafting challenging proposals, and 
provoking policy action. One lesson from these treaties is that 
support will have to be built from a strong coalition of like-
minded countries that would steer the process internationally.
While the development of the treaty is still at an early 
stage of discussion, the concept is already being aggressively 
opposed. As with tobacco, landmines, and more recently, 
sugar, the involvement of civil society will be crucial to defend 
these health improvement strategies where these may conﬂ ict 
with powerful vested interests in the private sector [19]. 
It takes courage to change the rules. If governments are 
indeed persuaded to face up to their responsibilities in 
the coming years, it may very well be because of the many 
voluntary organisations that seek to promote the global 
public interest. 
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